Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicityBenjamin L. Lampson, Jennifer R. Brown, Laura Z. Rassenti et al.|Blood|2016Cited by 289
A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patientsMatthew S. Davids, Jennifer R. Brown, David C. Fisher et al.|Leukemia|2020Cited by 36